ACTIONABILITY KNOWLEDGE REPOSITORY ACTIONABILITY CURATION INTERFACE
Update History
Condition: Primary pulmonary hypertension 1
Gene/Gene Panel: BMPR2
Context: Adult
Date
Status
Release
Outcomes-Interventions
Notes
2023/05/03
Released (Under revision)
1.2.4
A
Deterioration of pulmonary and cardiac function (GroupA)
Pharmacotherapy (GroupA) 8CA
Avoidance of exacerbating exposures (GroupA) 7CC
Annual echocardiogram (GroupA) 8CB
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
BMPR2 ⇔ 0024533 PULMONARY HYPERTENSION, PRIMARY, 1; PPH1
Moderate Actionability
Moderate Actionability
2022/03/14
Released
1.2.4
A
Deterioration of pulmonary and cardiac function (GroupA)
Pharmacotherapy (GroupA) 8CA
Avoidance of exacerbating exposures (GroupA) 7CC
Annual echocardiogram (GroupA) 8CB
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
BMPR2 ⇔ 0024533 PULMONARY HYPERTENSION, PRIMARY, 1; PPH1
Moderate Actionability
Moderate Actionability
2022/03/14
Released (Under revision)
1.2.3
A
Deterioration of pulmonary and cardiac function (GroupA)
Pharmacotherapy (GroupA) 8CA
Avoidance of exacerbating exposures (GroupA) 7CC
Annual echocardiogram (GroupA) 8CB
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
BMPR2 ⇔ 0024533 PULMONARY HYPERTENSION, PRIMARY, 1; PPH1
Moderate Actionability
Moderate Actionability
2022/02/21
Released
1.2.3
A
Deterioration of pulmonary and cardiac function (GroupA)
Pharmacotherapy (GroupA) 8CA
Avoidance of exacerbating exposures (GroupA) 7CC
Annual echocardiogram (GroupA) 8CB
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
BMPR2 ⇔ 0024533 PULMONARY HYPERTENSION, PRIMARY, 1; PPH1
Moderate Actionability
Moderate Actionability
2021/12/07
Released (Under revision)
1.2.2
A
Deterioration of pulmonary and cardiac function (GroupA)
Pharmacotherapy (GroupA) 8CA
Avoidance of exacerbating exposures (GroupA) 7CC
Annual echocardiogram (GroupA) 8CB
2020/04/27
Released
1.2.2
A
Deterioration of pulmonary and cardiac function (GroupA)
Pharmacotherapy (GroupA) 8CA
Avoidance of exacerbating exposures (GroupA) 7CC
Annual echocardiogram (GroupA) 8CB
2020/04/27
Released (Under revision)
1.2.1
A
Deterioration of pulmonary and cardiac function (GroupA)
Pharmacotherapy (GroupA) 8CA
Avoidance of exacerbating exposures (GroupA) 7CC
Annual echocardiogram (GroupA) 8CB
2020/04/27
Released
1.2.1
A
Deterioration of pulmonary and cardiac function (GroupA)
Pharmacotherapy (GroupA) 8CA
Avoidance of exacerbating exposures (GroupA) 7CC
Annual echocardiogram (GroupA) 8CB
2020/04/27
Released (Under revision)
1.2.0
A
Deterioration of pulmonary and cardiac function (GroupA)
Pharmacotherapy (GroupA) 8CA
Avoidance of exacerbating exposures (GroupA) 7CC
Annual echocardiogram (GroupA) 8CB
Internal system migration associated with Gene-Disease scoring groups upgrades.
2019/10/03
Released
1.2.0
A
Deterioration of pulmonary and cardiac function (GroupA)
Pharmacotherapy (GroupA) 8CA
Avoidance of exacerbating exposures (GroupA) 7CC
Annual echocardiogram (GroupA) 8CB
Internal system migration associated with Gene-Disease scoring groups upgrades.
2019/04/04
Released
1.1.0
A
Deterioration of pulmonary and cardiac function
Annual echocardiogram 8CB
Avoidance of exacerbating exposures 7CC
Pharmacotherapy 8CA
Internal system migration related to merging adult and pediatric contexts.
2018/11/01
Released
1.0.1
A
Deterioration of pulmonary and cardiac function
Annual echocardiogram 8CB
Avoidance of exacerbating exposures 7CC
Pharmacotherapy 8CA
Internal system migration related to score text replacement from E to N
2018/01/29
Released
1.0.0
A
Deterioration of pulmonary and cardiac function
Annual echocardiogram 8CB
Avoidance of exacerbating exposures 7CC
Pharmacotherapy 8CA
¤ Powered by BCM's Genboree.